US biotechnology company Biomilq has secured $21 million in Series A funding, as it aims to bring cell-cultured human milk to market.
The funding was led by global life science investor Novo Holdings, with participation from Breakthrough Energy Ventures, Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund and Gaingels.
The investment will help Biomilq produce cell-based human milk that mimics the nutritional value of human breast milk and with a lower carbon footprint than traditional bovine-based infant formula.
Kartik Dharmadhikari, Novo Holdings’ partner and Biomilq’s board director, said: “Our mission is to make a growing and positive impact on health, science and society. We are delighted to support Biomilq through its journey pioneering mammary biotechnology.”
Dharmadhikari continued: “Its products have the potential to disrupt the infant supplemental feeding industry. We aim to use our scientific knowledge, operational expertise and global network to further strengthen the company’s ability to improve lives.”
In 2020, Biomilq raised $3.5 million in funding to continue producing cultured breastmilk that offers supplemental nutrition to mother’s milk.
© FoodBev Media Ltd 2021
World Beverage Innovation Awards – NOW OPEN FOR ENTRIES!
The awards celebrate excellence and innovation across the global beverage industry.
Don’t miss out on having your innovations recognised on a global scale.
Deadline for entries 23 July – enter now!
Don’t get left behind
Start your free Foodbev magazine trial today and join thousands of fellow industry professionals in receiving food and drink trends direct to our business.
Click here to start your free trial